Clinical efficacy of NVB combined with cisplatin for 30 cases of advanced breast cancer after anthracycline chemotherapy

Objective To observe the clinical efficacy of NVB combined with cisplatin for patients with advanced breast cancer after anthracycline chemotherapy. Methods 60 cases of advanced breast cancer after anthracycline chemotherapy, admitted into our hospital from Sep 2010 to Aug 2011, were randomly divided into 2 groups： 30 patients in a test group got the treatment of NVB combined with cisplatin; 30 patients of the control group continued use of anthracycline chemotherapy. The treatment efficacy was calculated and observed.Results Effective rate （CR ＋ PR） in test group was 43.3%, which was higher than that （13.3%）in the control group, and the difference was statistically significant （P〈0.05）. After 3 courses of treatment, all patients had no severe liver functional damage occurred, and the main drug toxicity manifested as bone marrow suppression, gastrointestinal reactions, and hair loss; in addition, a small number of patients showed peripheral neurotoxicity and phlebitis; the difference of bone marrow suppression between 2 groups was statistically significant （P〈0.05）.Conclusion The treatment of NVB combined with eisplatin for the patients with advanced breast cancer after anthracycline chemotherapy is the best choice, which should be widely applied. Key words: Vinca alkali;  Cisplatin;  Breast cancer